StockData
Annexon, Inc. logo

Annexon, Inc. (ANNX) stock

ANNXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 5/30
$3.41−0.11 (-3.12%)

Close on Nov 19, 2026Market cap $697.16MP/E –Yield 0.00%

Annexon free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Annexon's free cash flow for the twelve months ending Jun 30, 2026 was -$193.22M. For fiscal 2025 it was -$186.49M. The highest annual figure on record is -$28.63M in fiscal 2019.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$186.49M–
FY2024Dec 31, 2024-$118.02M–
FY2023Dec 31, 2023-$121.34M–
FY2022Dec 31, 2022-$122.84M–
FY2021Dec 31, 2021-$107.76M–
FY2020Dec 31, 2020-$53.55M–
FY2019Dec 31, 2019-$28.63M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$48.14M–
Q1 FY2026Mar 31, 2026-$46.80M–
Q4 FY2025Dec 31, 2025-$45.93M–
Q3 FY2025Sep 30, 2025-$52.35M–
Q2 FY2025Jun 30, 2025-$38.09M–
Q1 FY2025Mar 31, 2025-$50.13M–
Q4 FY2024Dec 31, 2024-$36.02M–
Q4 FY2023Dec 31, 2023-$23.48M–
Q3 FY2023Sep 30, 2023-$28.31M–
Q2 FY2023Jun 30, 2023-$36.41M–
Q1 FY2023Mar 31, 2023-$33.13M–
Q4 FY2022Dec 31, 2022-$27.42M–
Q3 FY2022Sep 30, 2022-$30.89M–
Q2 FY2022Jun 30, 2022-$29.03M–
Q1 FY2022Mar 31, 2022-$35.50M–
Q4 FY2021Dec 31, 2021-$29.18M–
Q3 FY2021Sep 30, 2021-$30.48M–
Q2 FY2021Jun 30, 2021-$24.63M–
Q1 FY2021Mar 31, 2021-$23.47M–
Q4 FY2020Dec 31, 2020-$19.43M–
Q3 FY2020Sep 30, 2020-$13.86M–
Q4 FY2019Dec 31, 2019-$8.89M–
Q3 FY2019Sep 30, 2019-$7.02M–

More Annexon figures

See a number that looks wrong?